Literature DB >> 28870062

Initial clinical and hemodynamic results of a regional pulmonary thromboendarterectomy program.

Farhan Raza1, Anjali Vaidya1, Anne-Sophie Lacharite-Roberge2, Vladimir Lakhter1, Hayan Al-Maluli1, Irfan Ahsan3, Pamela Boodram4, Chandra Dass5, Frances Rogers1, Martin G Keane1, Sheila Weaver6, Riyaz Bashir1, Yoshiya Toyoda7, Paul Forfia8.   

Abstract

BACKGROUND: Pulmonary thromboendarterectomy (PTE) is the treatment of choice for eligible patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, access to CTEPH and PTE care is limited. There is a paucity of published data on PTE efficacy and outcomes from alternative, regional centers of excellence in CTEPH and PTE care in the USA, outside a single national and international referral center.
METHODS: We performed a retrospective review of patients undergoing PTE at our institution from June 2013 to December 2016 (42 months), and collected clinical, echocardiographic and hemodynamic data on our patients pre- and post-PTE (N.=71).
RESULTS: Patients age ranged between 20-83 years (mean±SD: 56±16), with 54% of patients female and 61% Caucasians. The predominant symptom was shortness of breath with a median duration of symptoms of 17 months. Following PTE, clinical improvements included a reduction in NYHA class from 3.1±1.1 to 2.2±1.2. There were major improvements in hemodynamics and echocardiographic parameters pre- versus post-PTE: mean pulmonary artery pressure (mmHg) 45±11 to 24±8, cardiac index (L/min/m2) 2.1±0.5 to 2.8±0.5, pulmonary vascular resistance (mmHg/L/min) 8.9±4.5 to 2.8±1.8, ratio of right ventricle (RV): left ventricle (LV) 1.2±0.3 to 0.9±0.2, RV fractional area change (%) 23±14 to 44±13, reduction in the incidence of RV outflow tract Doppler notching and improved pulmonary artery acceleration time (96% to 30%, and 74±19 to 111±21). In-hospital mortality was 4.2% (3 patients).
CONCLUSIONS: Herein, we report for the first time, the improvements in patient functionality, hemodynamics, right heart function and outcomes at a major regional PTE program.

Entities:  

Mesh:

Year:  2017        PMID: 28870062     DOI: 10.23736/S0021-9509.17.10188-6

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  4 in total

Review 1.  Recognizing pulmonary hypertension following pulmonary thromboendarterectomy: A practical guide for clinicians.

Authors:  Paul Forfia; Bruce Ferraro; Anjali Vaidya
Journal:  Pulm Circ       Date:  2022-06-07       Impact factor: 2.886

2.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

3.  Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest VE /VCO2 and ETCO2 identify pulmonary vascular disease.

Authors:  Farhan Raza; Naga Dharmavaram; Timothy Hess; Ravi Dhingra; James Runo; Amy Chybowski; Callyn Kozitza; Supria Batra; Evelyn M Horn; Naomi Chesler; Marlowe Eldridge
Journal:  Clin Cardiol       Date:  2022-04-14       Impact factor: 3.287

4.  Increased RV:LV ratio on chest CT-angiogram in COVID-19 is a marker of adverse outcomes.

Authors:  Ran Tao; Zuzana Burivalova; S Carolina Masri; Naga Dharmavaram; Aurangzeb Baber; Roderick Deaño; Timothy Hess; Ravi Dhingra; James Runo; Nizar Jarjour; Rebecca R Vanderpool; Naomi Chesler; Joanna E Kusmirek; Marlowe Eldridge; Christopher Francois; Farhan Raza
Journal:  Egypt Heart J       Date:  2022-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.